BioSpace News Archive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock.

Pfizer Inc. announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 4 million shares of Pfizer common stock at a price of $27.35 per share in cash.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced The New England Journal of Medicine (NEJM) has published data from the registrational Phase 1/2 TRIDENT-1 study evaluating repotrectinib (TPX-0005) in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancers (NSCLCs).

SOPHiA GENETICS (Nasdaq: SOPH) in a presentation at the 42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 a.m. PST.

Mirum Pharmaceuticals, Inc. announced that on January 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 50,950 shares of common stock and 25,480 restricted stock units to seven new employees under Mirum’s 2020 Inducement Plan.

Celltrion, Inc. announced the next phase of its strategic transformation from a developer of the world’s first monoclonal antibody biosimilar to an innovative company focused on new drug development at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Valneva SE announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.

The Centre for Chinese Herbal Medicine Drug Development of Hong Kong Baptist University (HKBU) has developed a new drug using effective components of a Chinese herbal medicine, Chaenomelis Fructus, for the treatment of the rare disease, myofibrillar myopathy.

Partners STADA and Alvotech announced that the European Commission issued a marketing authorization for Uzpruvo®, a biosimilar candidate to Stelara®.

Zomedica Corp. today announced that it will be hosting a conference call on Wednesday, January 17, 2024 at 4:30 p.m. ET.